Despite the pick-up in sales in the vaccines segment, GSK’s Q4 19 organic revenue growth decelerated to +2% due to a poor show in the pharmaceuticals segment – weighed down by generic and competitive pressure. Profitability was impacted by higher R&D spend and further pressure is on the cards as GSK tries to push new drugs into the market. The consumer healthcare JV restructuring programme should also be a short-term dampener, however, an IPO could help in unlocking value in t
12 Feb 2020
Sales momentum decelerates in Q4; margin to remain under pressure
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Sales momentum decelerates in Q4; margin to remain under pressure
GSK plc (GSK:LON) | 1,638 -245.8 (-0.9%) | Mkt Cap: 67,914m
- Published:
12 Feb 2020 -
Author:
Rishabh Kochar -
Pages:
4
Despite the pick-up in sales in the vaccines segment, GSK’s Q4 19 organic revenue growth decelerated to +2% due to a poor show in the pharmaceuticals segment – weighed down by generic and competitive pressure. Profitability was impacted by higher R&D spend and further pressure is on the cards as GSK tries to push new drugs into the market. The consumer healthcare JV restructuring programme should also be a short-term dampener, however, an IPO could help in unlocking value in t